Serotonin receptor blockade increases food intake and body weight after total gastrectomy in rats.
Serotonin receptor blockade increases food intake and body weight after total gastrectomy in rats.
复制标题
血清素受体阻断会增加大鼠全胃切除术后的食物摄入量和体重。
DOI：
--
复制
发表时间：
2002
影响因子：
2.2
通讯作者：
E. Jehle
中科院分区：
文献类型：
--
作者：
T. Zittel;J. Glatzle;T. Weimar;Steffen Kless;H. Becker;E. Jehle
背景
全胃切除术常导致早饱和体重减轻。全胃切除术后5-羟色胺抑制食物摄入，餐后5-羟色胺释放增加。血清素可能有助于全胃切除术后的早期饱腹感和体重减轻。
方法和材料
术后1-12个月，用自动记录系统对胃切除大鼠的摄食量和体重进行了研究。大鼠用甲麦角林、一种5-羟色胺（5-HT）（1/2）受体拮抗剂、两种不同的5-HT（3）受体拮抗剂、甲麦角林和devazepide的组合、一种胆囊收缩素（CCK）a受体拮抗剂或溶剂处理。此外，在全胃切除术后，通过腹膜内渗透微型泵连续应用甲麦角林或溶媒7、28或84天。
结果
Metergolin治疗导致胃切除大鼠的摄食量呈剂量依赖性增加。5-HT（3）受体拮抗剂治疗无影响，除甲麦角林外，地伐他汀也未进一步刺激摄食。术后1、3和6个月时，Metergoline使摄食量增加了45%（24小时累积摄食量[FI]，6个月：溶媒3.83 +/- 0.10，Metergoline 5.52 +/- 0.15 g/100 g体重（BW），P < 0.0001）。与赋形剂治疗相比，慢性甲麦角林治疗7、28或84天显著增加了全胃切除术后的摄食量（FI 7天：媒介物30.83 +/- 0.71，美替戈林36.27 +/- 0.85 g/100 g BW; P < 0.0002; 28天期间的平均每周FI;赋形剂31.23 +/- 0.22，美替戈林36.83 +/- 0.33 g/100 g BW，P < 0.0001; 84天内每周平均FI：媒介物33.02 +/-0.59，metergoline 35.07 +/-0.48 g/100 g BW，P < 0.008），并且与媒介物治疗相比，体重显著增加（7天：DeltaBW媒介物-0.7 +/-1.2 g vs DeltaBW美替戈林9.0 +/-2.1 g，P < 0.001; 28天：DeltaBW媒介物0.3 +/-2.2 vs DeltaBW美替戈林13.0 +/-2.3，P < 0.001; 84天：DeltaBW媒介物25.7 +/- 10.2对比DeltaBW甲麦角林49.5 +/- 7.2，P < 0.04）。处理84天导致显著的体重增加，而载体处理没有效果（载体：438 +/-11 g对464 +/-12 g，P < 0.2，n.s.;甲麦角林：448 +/- 9 g vs 498 +/- 10 g，P < 0.007）。
结论
5-羟色胺抑制食物摄入可能导致全胃切除术后早期饱腹感和体重减轻。
BACKGROUND
Total gastrectomy often results in early satiety and loss of body weight. Serotonin inhibits food intake, and postprandial serotonin release is increased after total gastrectomy. Serotonin might contribute to early satiety and loss of body weight after total gastrectomy.
METHODS AND MATERIALS
Food intake and body weight were investigated with an automated recording system in gastrectomized rats 1-12 months postoperatively. Rats were treated with metergoline, a 5-hydroxytryptamine (5-HT)(1/2) receptor antagonist, two different 5-HT(3) receptor antagonists, a combination of metergoline and devazepide, a cholecystokinin (CCK) a receptor antagonist, or vehicle. In addition, metergoline or vehicle was applied continuously by an intraperitoneal osmotic minipump for 7, 28, or 84 days after total gastrectomy.
RESULTS
Metergoline treatment resulted in a dose-dependent increase in food intake in gastrectomized rats. 5-HT(3) receptor antagonist treatment had no effect, and devazepide in addition to metergoline did not further stimulate food intake. Metergoline increased food intake at 1, 3, and 6 months postoperatively by up to 45% (24-h cumulative food intake [FI], 6 months: vehicle 3.83 +/- 0.10, metergoline 5.52 +/- 0.15 g/100 g body weight (BW), P < 0.0001). Chronic metergoline treatment for 7, 28, or 84 days significantly increased food intake after total gastrectomy compared to vehicle treatment (FI 7 days: vehicle 30.83 +/- 0.71, metergoline 36.27 +/- 0.85 g/100 g BW; P < 0.0002; average weekly FI during 28 days; vehicle 31.23 +/- 0.22, metergoline 36.83 +/- 0.33 g/100 g BW, P < 0.0001; average weekly FI during 84 days: vehicle 33.02 +/- 0.59, metergoline 35.07 +/- 0.48 g/100g BW, P < 0.008), and there was a significant body weight increase compared to vehicle treatment (7 days: DeltaBW vehicle -0.7 +/- 1.2 g vs DeltaBW metergoline 9.0 +/- 2.1 g, P < 0.001; 28 days: DeltaBW vehicle 0.3 +/- 2.2 vs DeltaBW metergoline 13.0 +/- 2.3, P < 0.001; 84 days: DeltaBW vehicle 25.7 +/- 10.2 vs DeltaBW metergoline 49.5 +/- 7.2, P < 0.04). Treatment for 84 days resulted in a significant body weight gain, while vehicle treatment had no effect (vehicle: 438 +/- 11 g vs 464 +/- 12 g, P < 0.2, n.s.; metergoline: 448 +/- 9 g vs 498 +/- 10 g, P < 0.007).
CONCLUSIONS
Inhibition of food intake by serotonin might contribute to early satiety and loss of body weight after total gastrectomy.
登录
查看更多内容
5-羟色胺-3受体激动剂引起猫呕吐的机制：迷走神经切断术、内脏切除术或后区病变的影响。
DOI：
--
发表时间：
1992
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
--
作者：
Miller,AD;Nonaka,S
通讯作者：
Nonaka,S
影响因子：
5
作者：
K. Miller;A. King;L. Demchyshyn;H. Niznik;M. Teitler
通讯作者：
K. Miller;A. King;L. Demchyshyn;H. Niznik;M. Teitler
DOI：
10.1152/ajpregu.1999.276.2.r429
发表时间：
1999-02-01
影响因子：
2.8
作者：
Burton-Freeman, B;Gietzen, DW;Schneeman, BO
通讯作者：
Schneeman, BO
DOI：
10.1007/978-3-0348-8845-5_3
发表时间：
1998
期刊：
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
影响因子：
--
作者：
Laszlo Prokai
通讯作者：
Laszlo Prokai
DOI：
10.5194/tc-13-3093-2019
发表时间：
2019-05
期刊：
The Cryosphere
影响因子：
--
作者：
M. Cooper;Thomas M. Jordan;D. M. Schroeder;M. J. Siegert;Christopher N. Williams;J. Bamber
通讯作者：
M. Cooper;Thomas M. Jordan;D. M. Schroeder;M. J. Siegert;Christopher N. Williams;J. Bamber